Back to results

TerminatedPhase 2

Safety and Efficacy Study of ABT-089 in Adults With Mild to Moderate Alzheimer's Disease

NCT00555204

What is this trial?

Generating plain-language summary...

Am I eligible?

Generating eligibility summary...

What's involved?

Summarizing study design...

Where and how to apply

Primary location

Phoenix, Arizona, United States

+41 additional locations

View on ClinicalTrials.gov

Save this trial

Quick facts

Start date: 2007-11
Enrollment: 337 participants
Sponsor: Abbott
Purpose: treatment

Locations (42)

Phoenix, Arizona, United States
Sun City, Arizona, United States
Fresno, California, United States
San Diego, California, United States
Santa Ana, California, United States
Santa Monica, California, United States
Hamden, Connecticut, United States
New Haven, Connecticut, United States
Brooksville, Florida, United States
Delray Beach, Florida, United States
Fort Myers, Florida, United States
Hallendale, Florida, United States
Hialeah, Florida, United States
Largo, Florida, United States
Miami, Florida, United States
Palm Beach Gardens, Florida, United States
Sunrise, Florida, United States
Tampa, Florida, United States
West Palm Beach, Florida, United States
West Palm Beach, Florida, United States
Indianapolis, Indiana, United States
Paducah, Kentucky, United States
Pittsfield, Massachusetts, United States
Grand Rapids, Michigan, United States
St Louis, Missouri, United States
Long Branch, New Jersey, United States
Nutley, New Jersey, United States
Princeton, New Jersey, United States
Ridgewood, New Jersey, United States
Albany, New York, United States
New York, New York, United States
Staten Island, New York, United States
The Bronx, New York, United States
Hickory, North Carolina, United States
Winston-Salem, North Carolina, United States
Centerville, Ohio, United States
Cleveland, Ohio, United States
Jenkintown, Pennsylvania, United States
Norristown, Pennsylvania, United States
San Antonio, Texas, United States
Wichita Falls, Texas, United States
Bennington, Vermont, United States

Safety and Efficacy Study of ABT-089 in Adults With Mild to Moderate Alzheimer's Disease — TrialFind